Hyperimmune Bovine Colostrum - TRAVELAN™ for Patients With Chronic Hepatitis C Virus Infection Not Responding to Standard Therapy

Inclusion Criteria: * Chronic HCV infection (genotype 1), as documented by a positive anti HCV titer, and confirmed by positive HCV RNA. * Non responder to previous antiviral therapy, HCV recurrence after 72 weeks of therapy, previous antiviral therapy stopped due to side effects, or not a candidate for treatment with interferon + ribavirin. * No antiviral therapy for at least 3 months. * HCV RNA ≥1,000 IU obtained within 30 days prior to study entry. * Not currently listed for liver transplantation * Female study subjects of reproductive potential (defined as girls who have reached menarche or women who have not been post-menopausal for at least 24 consecutive months, i.e., who have had menses within the preceding 24 months, or have not undergone a sterilization procedure (hysterectomy or bilateral oophorectomy) must have a negative serum or urine pregnancy test performed within 48 hours before initiating the protocol-specified medication(s) unless otherwise specified by product labeling. * All study subjects must agree not to participate in a conception process (e.g., active attempt to become pregnant or to impregnate, sperm donation, in vitro fertilization). * If participating in sexual activity that could lead to pregnancy, the study volunteer must agree that two reliable methods of contraception will be used simultaneously while receiving the protocol-specified medication and for 1 month after stopping the medication. NOTE: Hormonal-based methods alone are not sufficient. At least two of the following methods MUST be used appropriately unless documentation of menopause, sterilization, or azoospermia is present: * Condoms (male or female) with or without a spermicidal agent. Condoms are recommended because their appropriate use is the only contraception method effective for preventing HIV transmission; * Diaphragm or cervical cap with spermicide; * IUD; * Hormonal-based contraception. * Study subjects who are not of reproductive potential (girls who have not reached menarche or women who have been post-menopausal for at least 24 consecutive months or have undergone hysterectomy and/or bilateral oophorectomy are eligible without requiring the use of contraceptives. Written or oral documentation communicated by clinician or clinician's staff is required by one of the following: * Physician report/letter; * Operative report or other source documentation in the patient record (a laboratory report of azoospermia is required to document successful vasectomy); * Discharge summary; * Laboratory report of azoospermia; * FSH measurement elevated into the menopausal range as established by the reporting laboratory. * Men and women age \> 18 years. * Ability and willingness of subject or legal guardian/representative to provide informed consent. Exclusion Criteria: * Pregnancy or Breast-Feeding * Continuous use of the following medications for more than 3 days within 30 days of study entry: * Immunosuppressives; * Immune modulators; * Systemic glucocorticoids; * Anti-neoplastic agents; * Active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements. * Serious illness requiring systemic treatment and/or hospitalization within 30 days prior to entry.